Lower Viable CD34 Recovery in Cryopreserved Allogeneic PBSC Compared to Autologous PBSC

Cryopreservation of adult unrelated donor products in hematopoietic cell transplantation: the OneMatch experience and systematic review of the literature

“…The 32 studies that met the inclusion criteria described a total of 993 patients, and half of these studies were published before 2000 . The studies were from groups in North America (12), Europe (15), Asia (four), and elsewhere (one).…”

“…Moreover, 57% of study participants were males. Some studies have been published as abstracts only [7][8][9][10][11][12][13][14][15] or letter to the editor, 16 while a majority of the included studies were full publications. A subset of studies provided data on hematopoietic engraftment and the impact of cryopreservation on cell yield in comparison to controls.…”

“…Moreover, no apparent difference in CD341 cells infused (eight studies 9,14,[17][18][19]21,29,31 ) was reported for patients receiving cryopreserved products compared to controls receiving fresh products ( Table 5). The yield of CD341 cells available after thawing was 31% to 100% (data reported in eight studies 9,13,21,24,26,[35][36][37] ). Only 13 studies 12,13,[16][17][18][19][20]26,30,32,35,36,38 (40% of studies, reporting on 575 patients or 57.9% of total) reported reasons for performing cryopreservation.…”

“…The yield of CD341 cells available after thawing was 31% to 100% (data reported in eight studies 9,13,21,24,26,[35][36][37] ). Only 13 studies 12,13,[16][17][18][19][20]26,30,32,35,36,38 (40% of studies, reporting on 575 patients or 57.9% of total) reported reasons for performing cryopreservation. While most studies reported more than one reason for performing cryopreservation, few specified the precise number of products for each cited reason.…”

“…Number of days to ANC of >0.5 3 10 9 /L (n 5 18 studies) 9-21. 12,13,[16][17][18][19][20]26,30,32,35,36,38 Reason for cryopreservation request was possible. The impact of cryopreservation on hematopoietic engraftment appears negligible when compared to controls although more systematic reporting in studies that includes mean values for rates of engraftment and yields of viable total cells and CD341 cells will be needed to increase confidence and allow for pooled metaanalysis.…”